Surgical implications of platelet glycoprotein IIb-IIIa inhibition [3]

Journal of Thoracic and Cardiovascular Surgery

Volumn 116, Issue 6, 1998, Pages 1083-1084

  Dyke, C ^a   Gammie, J ^a  

^a Carolinas Heart Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; APROTININ; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; EMERGENCY SURGERY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031759936     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(98)70069-8     Document Type: Letter

References (3)

1. JM. Alvarez Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab J Thorac Cardiovasc Surg 115 1998 472 473
2. JS Gammie M Zenati RL Kormos BG Hattler LM Wei RV Pellegrini Abciximab and excessive bleeding in patients undergoing emergency cardiac operations Ann Thorac Surg 65 1998 465 469
3. EJ. Topol Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence Circulation 97 1998 211 218